ArticleAntimicrobial agents and chemotherapy1994
Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa.
Article in Antimicrobial agents and chemotherapy, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Macrolide antibiotics (including azithromycin) for cystic fibrosis.The Cochrane database of systematic reviews · 2024Pooled it
- Macrolide antibiotics for cystic fibrosis.The Cochrane database of systematic reviews · 2012Pooled it
- Spiramycin DisarmsAntibiotics (Basel, Switzerland) · 2023Article
- Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine.Microorganisms · 2022Review
- Autoinducer Analogs Can Provide Bactericidal Activity to Macrolides inAntibiotics (Basel, Switzerland) · 2021Article
- Sub-Inhibitory Antibiotic Exposure and Virulence inAntibiotics (Basel, Switzerland) · 2021Review
- Could Azithromycin Be Part ofFrontiers in microbiology · 2021Review
- Azithromycin Exhibits Activity AgainstFrontiers in microbiology · 2021Article
- Drugs with new lease of life as quorum sensing inhibitors: for combating MDR Acinetobacter baumannii infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Macrolides Inhibit Capsule Formation of Highly VirulentAntimicrobial agents and chemotherapy · 2019Article
- Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.Annals of the American Thoracic Society · 2018Article
- A diketopiperazine factor from Rheinheimera aquimaris QSI02 exhibits anti-quorum sensing activity.Scientific reports · 2016Article
- In vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa and its modulation by azithromycin.Journal of translational medicine · 2015Article
- Choosing an appropriate infection model to study quorum sensing inhibition in Pseudomonas infections.International journal of molecular sciences · 2013Review
- Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.Inflammopharmacology · 2013Review
- Exploiting quorum sensing to confuse bacterial pathogens.Microbiology and molecular biology reviews : MMBR · 2013Review
- Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2011Article
- Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Clinical microbiology reviews · 2010Review
- Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2008Article
- Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.Antimicrobial agents and chemotherapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inhibitory effects of azithromycin (AZM), a new 15-membered macrolide antibiotic, on the production of exotoxin A, total protease, elastase, and phospholipase C by Pseudomonas aeruginosa were determined, and the virulence-suppressing effects of AZM were compared with those of erythromycin (EM), roxithromycin (RXM), and rokitamycin (RKM). The effect of exposure of P. aeruginosa PA103 or B16 in cultures to sub-MICs of these macrolide antibiotics on the production of exoenzymes was determined. AZM suppressed the in vitro production of extracellular and intracellular exotoxin A by P. aeruginosa PA103 more than did EM, even at a concentration of only 2 micrograms/ml. At concentrations of between 4 and 32 micrograms/ml, AZM also inhibited total protease, elastase, and phospholipase C production by P. aeruginosa B16 more than did EM, RXM, and RKM. AZM was effective in suppressing exotoxin A and total protease production through 24 h of incubation in the presence of drug at sub-MICs, but it had no significant effect on either the growth of P. aeruginosa or its total protein production. Moreover, at a concentration of 4 micrograms/ml, AZM suppressed exoenzyme production by other strains of P. aeruginosa more than did EM. These findings indicate that AZM, EM, RXM, and RKM each has an inhibitory effect on exoenzyme production separate from the antimicrobial effect and that, of these macrolides, AZM has the strongest virulence-suppressing effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.